Cured mice that had received anti-PD-1 monotherapy exhibited the best tumour rejection rate (8/8, 100%), and all of them displayed optimal immune memory, with no tumour growth detectable in any of the mice after the re-challenge experiment. This evidence concerns the gene PDCD1 and neoplasm.